PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

Abstract

Authors

C. Smare K. Dave A. Juarez-Garcia N. Schoenherr P. Abraham J.R. Penrod D.R. Camidge Y. Yuan